

# **United States Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals, Oncology Center, Long Term Care Center), By Region, Competition, Forecast and Opportunities, 2018-2028F**

<https://marketpublishers.com/r/U6C4D58407CEEN.html>

Date: November 2023

Pages: 90

Price: US\$ 3,500.00 (Single User License)

ID: U6C4D58407CEEN

## **Abstracts**

United States Soft Tissue Sarcoma Market is anticipated to project steady growth in the forecast period. Soft tissue sarcoma is a rare type of cancer that originates in the intricate network of tissues responsible for connecting, supporting, and enveloping various structures within the body. These tissues encompass muscles, adipose tissue, blood vessels, nerves, tendons, and the synovial lining of joints. Soft tissue sarcoma has the potential to manifest in any part of the body, but it predominantly occurs in the extremities - arms and legs, as well as the chest or abdomen.

Symptoms of soft tissue sarcoma may include the presence of a palpable lump or swelling, accompanied by localized pain if the sarcoma exerts pressure on adjacent nerves or muscles. In certain cases, sarcomas located in the chest can cause respiratory difficulties, making breathing uncomfortable. It is worth noting that, like most cancers, early detection of soft tissue sarcoma coupled with timely treatment significantly enhances the prospects of successful recovery.

### **Key Market Drivers**

Increased Prevalence of Soft Tissue Sarcoma in The Population

The increasing prevalence of Soft Tissue Sarcoma (STS) in the United States has elevated the demand for effective treatments and therapies. Sarcomas, a relatively rare group of cancers, have seen a noticeable uptick in occurrences, particularly in soft tissues which constitute about 80% of sarcoma cases. This increase has been attributed to various factors including improved diagnostic techniques, increased awareness, and lifestyle changes. Consequently, this rise in STS incidents has led to a surge in demand for treatments, with an expectation of further escalation. The healthcare industry is responding by investing in cutting-edge research, novel therapeutic techniques, and advanced pharmaceuticals to effectively combat STS. Additionally, the adoption of personalized medicine and genomics in treatment plans is also being widely incorporated. This growth in STS cases has also instigated a push for better insurance coverage for comprehensive treatment plans. With the culmination of these factors, the demand for STS treatments in the United States is likely to continue its upward trajectory, necessitating further advancements in medical science and healthcare policies.

#### Advancements in Diagnostic Technologies

The advancements in diagnostic technologies are anticipated to propel the demand for Soft Tissue Sarcoma (STS) treatments in the United States. Emerging technologies, such as high-resolution imaging techniques, genomics, and liquid biopsies, are providing more accurate and timely diagnosis of STS. Such technologies enable the identification of STS at an early stage when it is most treatable, thereby increasing the demand for STS treatments. Additionally, advancements in genomic analysis have paved the way for personalized medicine, where treatments can be tailored to the specific genetic makeup of the patient's tumor. This advancement is expected to increase the treatment effectiveness and survival rates for STS patients, thereby driving demand. These technologies also reduce the need for invasive diagnostic procedures, making the diagnosis process more comfortable for patients. Furthermore, the U.S. healthcare system's robust infrastructure and high spending on healthcare are expected to facilitate the adoption of these advanced diagnostic technologies. As a result, more individuals who were previously unaware of their condition can be diagnosed and treated, leading to an increase in the demand for STS treatments.

#### Development of Novel and Effective Therapeutics

With the growing prevalence of soft tissue sarcoma (STS) in the United States, demand for novel and effective therapeutics is expected to escalate. STS, a rare type of cancer that occurs in the soft tissues like muscles, tendons, fat, lymph vessels, blood vessels,

and nerves, carries a significant death risk and substantial morbidity. Despite advancements in surgical techniques and radiotherapy, the survival rate of patients with STS has not improved substantially over the years, underscoring the pressing need for innovative treatment modalities. Therefore, the development of novel therapeutics is an area of immense focus and investment. Scientists and pharmaceutical companies are rigorously working on targeted therapies and immunotherapies showing promising results in clinical trials. As these new treatments become available, they are expected to increase the demand for STS treatment, fueling the growth of the STS market. The potential to provide a more effective treatment option for STS patients, coupled with an increasing incidence of STS, is anticipated to bolster the demand for these novel and effective therapeutics in the United States.

### Increased Investment by Pharmaceutical Companies in Cancer Research

The growing investment by pharmaceutical companies in cancer research is anticipated to significantly boost the demand for soft tissue sarcoma treatments in the United States. This surge in demand can be attributed to advancements in molecular biology and genomics, which have led to the development of innovative and effective therapeutics. Increased funding has allowed for more comprehensive research, leading to a better understanding of the disease and the identification of potential targets for treatment. Researchers have discovered specific genetic mutations and biomarkers that play a role in the development and progression of soft tissue sarcoma, paving the way for targeted therapies tailored to individual patients.

Moreover, enhanced diagnostic techniques, such as advanced imaging technologies and liquid biopsies, have improved the early detection of soft tissue sarcoma. Early diagnosis enables timely intervention and increases the likelihood of successful treatment outcomes.

Furthermore, the emergence of personalized medicine and targeted therapies, fueled by these investments, has shown promising results in the management of soft tissue sarcoma. By analyzing the unique genetic profile of each patient's tumor, medical professionals can select the most appropriate treatment options, minimizing side effects and optimizing treatment efficacy. Collectively, these factors are expected to drive the demand for soft tissue sarcoma treatments in the United States, reflecting the positive impact of increased investment in cancer research. With ongoing advancements and continued investment, the future holds even greater potential for improved outcomes and quality of life for individuals affected by soft tissue sarcoma.

## Key Market Challenges

### Side Effects Associated with The Current Treatment Options

The prevalence of Soft Tissue Sarcoma (STS) in the United States has led to a significant demand for effective treatment options. However, the current treatment methods are often accompanied by severe side effects, which are expected to counteract this demand. Traditional treatments such as chemotherapy, radiation, and surgery, while effective, can result in debilitating side effects including fatigue, nausea, hair loss, and even the development of secondary cancers. As a result, many patients may be hesitant to pursue these treatment options due to concerns about their quality of life and overall well-being.

Furthermore, the high costs associated with these treatments can also contribute to the anticipated decrease in demand. Patients may face financial burdens that make these treatment options inaccessible, further complicating the decision-making process. Recognizing these challenges, the medical community is increasingly emphasizing the importance of patient comfort and well-being in the development of innovative therapies for STS. The goal is to minimize side effects while still achieving positive treatment outcomes.

As the medical field continues to advance, there is a growing focus on the development of patient-friendly and cost-effective therapies for STS. Researchers and clinicians are exploring new treatment modalities that have the potential to provide effective outcomes with fewer side effects. By prioritizing patient comfort and well-being, the future of STS treatment in the United States is expected to shift towards more targeted and personalized approaches that not only address the disease but also enhance the overall quality of life for patients.

While the demand for STS treatment remains high, the presence of severe side effects and associated costs pose significant challenges. However, with the medical community's commitment to patient comfort and the ongoing development of innovative therapies, there is hope for a future where STS treatment options are more tailored, effective, and accessible, ultimately improving the lives of those affected by this condition.

### High Cost of Therapies

The high cost of therapies for soft tissue sarcoma (STS) is likely to decrease demand

for these treatments in the United States. STS therapies, including surgery, radiation, and chemotherapy, are not only expensive but also complex, often requiring specialized care teams and extended treatment durations. According to the American Cancer Society, the average cost of cancer treatment can be in the range of several tens of thousands of dollars. This places a serious financial burden on patients, potentially leading to 'financial toxicity,' a term used to describe the severe economic stress that patients often face due to their treatment costs. For patients without comprehensive health insurance, the financial strain can be even more substantial, potentially making treatment unattainable. As a result, the high cost of STS therapies could decrease their demand as patients seek more affordable alternatives or potentially delay treatment due to cost concerns. In addition, high therapy costs could also impact hospitals and healthcare providers, who may struggle to provide these expensive treatments to uninsured or underinsured patients. As such, it's imperative that steps are taken to address these financial barriers to ensure that all STS patients can access the life-saving treatments they need.

## Key Market Trends

### Expansion of Personalized Medicine

The expansion of personalized medicine is anticipated to significantly drive the demand for soft tissue sarcoma treatment in the United States. Personalized medicine, a rapidly emerging approach to healthcare, tailors treatment to each patient's unique genetic makeup, lifestyle, and environmental factors. This approach is especially influential in the management of soft tissue sarcoma, a diverse group of rare cancers that occur in muscles, fat, blood vessels, deep skin tissues, tendons, and ligaments. Personalized medicine can help identify specific genetic mutations involved in the growth of these sarcomas, allowing for targeted therapies that will likely improve patient outcomes. Additionally, personalized medicine may support early detection of soft tissue sarcoma, contributing to increased treatment demand. As the United States healthcare system continues to embrace this innovative approach, it is feasible to predict an uptick in the demand for specialized treatments for soft tissue sarcoma, bolstering its market growth. Furthermore, the rise of genomics and precision medicine, complemented by the country's advanced healthcare infrastructure and policies that support healthcare innovation, further reinforce this prediction.

### Increasing Adoption of Targeted Therapy and Immunotherapy

The increasing adoption of targeted therapies and immunotherapies is anticipated to

drive demand for the treatment of Soft Tissue Sarcoma (STS) in the United States. STS, a rare type of cancer that begins in the soft tissues, has traditionally been treated using conventional methods such as surgery, radiation, and chemotherapy. However, with recent advancements in medical research, targeted therapies and immunotherapies are emerging as promising alternatives. Targeted therapies work by targeting specific genes or proteins that contribute to the growth and survival of cancer cells, whereas immunotherapies aim to strengthen the body's immune system to fight cancer. These therapies offer enhanced efficacy and reduced side effects, making them more appealing to both patients and healthcare providers. Moreover, the personalized nature of these treatments, which can be tailored to individual patients based on molecular and genetic profiles, makes them even more effective. The rise in patient awareness, coupled with a growing emphasis on personalized medicine, is expected to further fuel the adoption of these therapies for STS treatment. Therefore, the increased utilization of targeted therapies and immunotherapies is set to significantly boost the STS treatment market in the United States.

## Segmental Insights

### Treatment Insights

Based on the Treatment, targeted therapy is anticipated to dominate the United States Soft Tissue Sarcoma Market. This innovative treatment approach harnesses the power of precision medicine, specifically targeting cancer cells while minimizing harm to healthy tissues. Compared to traditional therapies like Chemotherapy and Radiation Therapy, Targeted Therapy offers a promising alternative with fewer side-effects, enhancing the quality of life for patients. Furthermore, as the field of oncology continues to evolve, new avenues such as Anti-Angiogenesis Drugs are being explored. These drugs hold immense potential in inhibiting the growth of blood vessels that supply tumours, thereby restricting their nourishment and growth. While their full potential is yet to be fully realized in the treatment landscape, the recognition of their therapeutic value propels the field forward. With the current trends and advancements, it is evident that Targeted Therapy is poised to not only lead but revolutionize the Soft Tissue Sarcoma Market, offering hope and improved outcomes for patients.

### Disease Type Insights

Based on the Disease Type, among various disease types, one that holds a significant market share is Metastatic Sarcoma. This can be attributed to the disease's inherent complexity and aggressive nature, which often necessitate extensive and intensive



treatment options. Patients diagnosed with Metastatic Sarcoma face a challenging battle, as the disease tends to spread rapidly to other parts of the body, making it difficult to treat effectively. Due to the high demand for effective therapies, the market for addressing this condition experiences substantial growth. Healthcare providers and researchers are diligently working together to explore innovative approaches and treatment strategies to combat this challenging disease. They aim to improve patient outcomes and enhance the quality of life for individuals living with Metastatic Sarcoma.

Advancements in precision medicine, immunotherapy, and targeted therapies offer promising avenues for improving treatment efficacy and reducing side effects. Additionally, ongoing research efforts focus on identifying genetic and molecular markers that can help personalize treatment plans and optimize patient care. By continuously pushing the boundaries of medical knowledge and innovation, healthcare professionals strive to provide better outcomes and hope for individuals affected by Metastatic Sarcoma. Through collaborative efforts, the medical community aims to develop comprehensive and individualized treatment approaches that address the complex nature of this disease.

## Regional Insights

The West region of the United States is currently dominating the Soft Tissue Sarcoma Market. This can be attributed to several factors including the region's advanced healthcare infrastructure, the presence of key market players, and a high concentration of research institutes conducting extensive studies on soft tissue sarcoma. In the West region, there are renowned medical centers and hospitals that specialize in sarcoma treatment, offering state-of-the-art facilities and a multidisciplinary approach to patient care. These institutions have a long-standing reputation for excellence in research and clinical expertise, attracting top-tier medical professionals and researchers from around the world.

Moreover, the collaborative environment in the West region plays a significant role in driving advancements in the field of soft tissue sarcoma. Healthcare professionals, researchers, and industry experts come together in this region, fostering a rich exchange of knowledge, ideas, and resources. This synergy of expertise and resources fuels innovation and facilitates the development of groundbreaking treatment approaches, diagnostic techniques, and therapeutic interventions.

The West region's commitment to comprehensive care extends beyond treatment options. Patients in this region have access to the latest clinical trials, cutting-edge

technologies, and personalized care plans tailored to their specific needs. This patient-centric approach ensures that individuals diagnosed with soft tissue sarcoma receive the most effective and individualized treatment possible. With its robust healthcare ecosystem, collaborative research environment, and focus on patient-centered care, the West region has emerged as a prominent hub for soft tissue sarcoma management and research. This region continues to lead the way in advancing our understanding of this complex disease, offering hope and improved outcomes for patients not only within the United States but also worldwide.

### Key Market Players

GlaxoSmithKline LLC

Eli Lilly and Company

Pfizer Inc.

Bristol-Myers Squibb Co.

Hoffmann-La Roche, Inc.

Johnson & Johnson

Teva Pharmaceuticals USA, Inc.

Celgene Corporation

Zimmer Biomet Holdings, Inc.

MIMEDX Group, Inc.

### Report Scope:

In this report, the United States Soft Tissue Sarcoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

### United States Soft Tissue Sarcoma Market, By Treatment:



Targeted Therapy

Chemotherapy

Anti-Angiogenesis Drug

Radiation Therapy

United States Soft Tissue Sarcoma Market, By Disease Type:

Local Sarcoma

Regional Sarcoma

Metastatic Sarcoma

United States Soft Tissue Sarcoma Market, By End User:

Hospitals

Oncology Center

Long Term Care Center

United States Soft Tissue Sarcoma Market, By Region:

Northeast Region

Midwest Region

West Region

South Region

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Soft Tissue Sarcoma Market.

*United States Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug,...*

#### Available Customizations:

United States Soft Tissue Sarcoma Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

#### Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. UNITED STATES SOFT TISSUE SARCOMA MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy)
  - 5.2.2. By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma)
  - 5.2.3. By End User (Hospitals, Oncology Center, Long Term Care Center)

- 5.2.4. By Region
- 5.2.5. By Company (2022)
- 5.3. Market Map

## **6. NORTH-EAST SOFT TISSUE SARCOMA MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Treatment
  - 6.2.2. By Disease Type
  - 6.2.3. By End User

## **7. MID-WEST SOFT TISSUE SARCOMA MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Treatment
  - 7.2.2. By Disease Type
  - 7.2.3. By End User

## **8. WEST SOFT TISSUE SARCOMA MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Treatment
  - 8.2.2. By Disease Type
  - 8.2.3. By End User

## **9. SOUTH SOFT TISSUE SARCOMA MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Treatment
  - 9.2.2. By Disease Type
  - 9.2.3. By End User

## **10. MARKET DYNAMICS**

- 10.1. Drivers
- 10.2. Challenges

## **11. MARKET TRENDS & DEVELOPMENTS**

- 11.1. Recent Development
- 11.2. Mergers & Acquisitions
- 11.3. Product Launches

## **12. POLICY & REGULATORY LANDSCAPE**

## **13. UNITED STATES ECONOMIC PROFILE**

## **14. UNITED STATES SOFT TISSUE SARCOMA MARKET: SWOT ANALYSIS**

## **15. PORTER'S FIVE FORCES ANALYSIS**

- 15.1. Competition in the Industry
- 15.2. Potential of New Entrants
- 15.3. Power of Suppliers
- 15.4. Power of Customers
- 15.5. Threat of Substitute Products

## **16. COMPETITIVE LANDSCAPE**

- 16.1. GlaxoSmithKline LLC
  - 16.1.1. Business Overview
  - 16.1.2. Product Offerings
  - 16.1.3. Recent Developments
  - 16.1.4. Financials (As Reported)
  - 16.1.5. Key Personnel
- 16.2. Eli Lilly and Company
- 16.3. Pfizer Inc.
- 16.4. Bristol-Myers Squibb Co.
- 16.5. Hoffmann-La Roche, Inc.
- 16.6. Johnson & Johnson

16.7. Teva Pharmaceuticals USA, Inc.

16.8. Celgene Corporation

16.9. Zimmer Biomet Holdings, Inc.

16.10. MIMEDX Group, Inc.

## **17. STRATEGIC RECOMMENDATIONS**

## **18. ABOUT US & DISCLAIMER**



## I would like to order

Product name: United States Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals, Oncology Center, Long Term Care Center), By Region, Competition, Forecast and Opportunities, 2018-2028F

Product link: <https://marketpublishers.com/r/U6C4D58407CEEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U6C4D58407CEEN.html>